Sesen Bio — Eleven Biotherapeutics — Investor Presentation (October 2017)
39 slides from Sesen Bio's investor presentation, Oct 20, 2017
Slide 1: Targeting Cancer with POWER+PRECISION
© 2017 Eleven Biotherapeutics. All rights reserved. © 2017 Eleven Biotherapeutics. All rights reserved. Targeting Cancer with POWER+PRECISION™
Slide 2: Forward-looking statements
© 2017 Eleven Biotherapeutics. All rights reserved. This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future o
Slide 3: Eleven Biotherapeutics
© 2017 Eleven Biotherapeutics. All rights reserved. Eleven Biotherapeutics • Cambridge, Massachusetts-based company founded in 2010 by Flagship and Third Rock Ventures to engineer protein therapeutics (NASDAQ:EBIO) • In August 2016, we granted Roche an exclusive license to EBI-031, a humanized monoc
Slide 4: Investment Rationale
© 2017 Eleven Biotherapeutics. All rights reserved. Investment Rationale Broad pipeline of locally and systemically administered product candidates for future development • ProxiniumTM, for squamous cell carcinoma of the head and neck (SCCHN) - Anti-tumor activity demonstrated in over 100 patients i
Slide 5: Product Pipeline
© 2017 Eleven Biotherapeutics. All rights reserved. Product Candidate Payload Indication Preclinical Ph 1 Ph 2 Ph 3 Locally administered TPTs Vicinium ETA BCG refractory high-grade NMIBC Locally administered TPT + Systemic Checkpoint Inhibitor Vicinium + Durvalumab ETA & IO BCG refractory high-grade
Slide 6: Projected Newsflow
© 2017 Eleven Biotherapeutics. All rights reserved. NCI/ AZ - Vicinium + durvalumab NMIBC Phase 1 first patient treated Q4 2017 VISTA - Vicinium NMIBC Phase 3 complete enrollment Q1 2018 VISTA - Vicinium NMIBC Phase 3 topline three-month data Mid 2018 NCI/AZ - Vicinium + durvalumab NMIBC Phase 1 ini
Slide 7: Targeted Protein Therapeutics structure
© 2017 Eleven Biotherapeutics. All rights reserved. Targeted Protein Therapeutics (TPTs) are expressed as a single protein molecule comprised of an anti-tumor antibody fragment, a tether and a cytotoxic payload Can be designed either for loco-regional or systemic delivery Antibody Fragment Tether Pr
Slide 8: TPTs Designed to Overcome Limitations of Existing ADCs
© 2017 Eleven Biotherapeutics. All rights reserved. TPTs Designed to Overcome Limitations and Improve on Existing ADCs • TPTs are designed to deliver a greater amount of drug to the tumor with deeper penetration and faster systemic elimination ‒ Utilize antibody fragments instead of intact Mabs • Ar
Slide 9: TPT Mechanism of Action
© 2017 Eleven Biotherapeutics. All rights reserved. 9 TPT Mechanism of Action Focused delivery and potent anti-cancer effect
Slide 10: TPTs Induce Immunogenic Cell Death
© 2017 Eleven Biotherapeutics. All rights reserved. TPTs Induce Immunogenic Cell Death Suggests Second Mechanism of Action, Synergy with I-O Agents • Preclinical and clinical trial data suggest that VB4 (Vicinium and Proxinium) is promoting host anti-tumor immune responses ‒ Immune checkpoint therap
Slide 11: Vicinium
© 2017 Eleven Biotherapeutics. All rights reserved. An anti-EpCAM single chain Fv antibody fragment fused to Pseudomonas Exotoxin A to create a potent single protein therapeutic Vicinium is in an active Phase 3 Registration Trial for the Treatment of High-Grade NMIBC 11
Slide 12: Vicinium Overview
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium Overview Extremely Potent • Subpicomolar IC50 Targeting EpCAM in NMIBC • >98% of high grade NMIBCs express EpCAM in prior studies • Minimal to no EpCAM expression on normal bladder cells Phase I and Phase 2 completed • Demonstrated complet
Slide 13: Bladder Cancer
© 2017 Eleven Biotherapeutics. All rights reserved. Bladder Cancer • Approx. 75-85% of new bladder cancer cases are NMIBC ‒ Ta: 57% -75% • Low-grade: 77% • High-grade: 23% ‒ T1: 20-30% - almost all high grade ‒ CIS: 5-13% - all high grade Proprietary and Confidential 13
Slide 14: Opportunity in Bladder Cancer
© 2017 Eleven Biotherapeutics. All rights reserved. Opportunity in Bladder Cancer In US, bladder cancer is the 6th most common1 but the most expensive cancer to treat with indirect costs ranging from $184,762 to $461,907 per patient2 • In 2014 the prevalence of bladder cancer was 696,440 in the US3
Slide 15: Current Approach After BCG Failure
© 2017 Eleven Biotherapeutics. All rights reserved. Current Approach After BCG Failure No Major Advances in 30 Years • Survivors of initial treatment face a life-long risk of recurrence with stage progression ‒ 30% risk of dying from bladder cancer • Radical cystectomy is the primary recommendation
Slide 16: NMIBC: BCG Failure Leads to Cystectomy
© 2017 Eleven Biotherapeutics. All rights reserved. 16 NMIBC: BCG Failure Leads to Cystectomy* *Adapted from Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline, 2016 Low Risk Int. Risk High Risk TURBT Postoperative Chemo Surveillance Reassess as Int. Risk Re-TURBT +/-Ch
Slide 17: Development of Drugs and Biologics for NMIBC
© 2017 Eleven Biotherapeutics. All rights reserved. Development of Drugs and Biologics for NMIBC In November 2016, the FDA released draft guidance “BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment - Guidance for Industry: ‒ CIS is not completely resect
Slide 18: Vicinium Phase 1 Clinical Results
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium: Phase 1 Clinical Results • 64 patients with Grade 2 or 3 BCG refractory or intolerant EpCAM “+” NMIBC* • Trial design ‒ Treated weekly x 6 weeks ‒ Dose escalation (0.1- 30.16 mg) ‒ Efficacy assessment ‒ Cystoscopy, Biopsy (Random and Dire
Slide 19: Vicinium Phase 2 Trial
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium Phase 2 Trial • Design: Phase 2 Trial evaluating two induction schedules followed by maintenance treatment, all treatments once weekly • Study Population: Patients with EpCAM+ CIS (+/- papillary disease) previously treated with BCG in the
Slide 20: Vicinium Phase 2 Trial: Safety Results
© 2017 Eleven Biotherapeutics. All rights reserved. • No significant toxicity or tolerability issues ‒ Generally well tolerated ‒ No subjects unable to complete treatment ‒ 65% of subjects had an AE related to treatment • The majority being local bladder ‒ Three subjects reported SAEs. None of the S
Slide 21: Vicinium Phase 2 Trial: Efficacy Results
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium Phase 2 Trial: Efficacy Results Source: Kowalski et. al., Drug Design, Development and Therapy 4: 313, 2010. • CR rates ‒ Three months: 40.9% (cohort 1) and 39.1% (cohort 2) ‒ 12 months: 13.6% (cohort 1) and 17.4% (cohort 2) • All patients
Slide 22: Rationale for Increasing Frequency of Dosing
© 2017 Eleven Biotherapeutics. All rights reserved. -100 0 100 200 300 Combined Phase 2 data CIS with or without Ta, T1 Increased Area Affected Stable Disease (SD) Partial Response (PR) Complete Responders (CR) • 73% of non CRs had clinical benefit • Two patients in Phase 2, Arm 1 achieved a CR afte
Slide 23: Phase 3 VISTA Study
An Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Tolerability of Intravesical ViciniumTM in Subjects with Non Muscle Invasive Carcinoma in Situ (CIS) and/or High-Grade Papillary Disease of the Bladder Previously Treated with Bacillus Calmette Guérin (BCG) https://clinicaltrials
Slide 24: Phase 3 Study Design and Endpoints
© 2017 Eleven Biotherapeutics. All rights reserved. 24 Phase 3 Study Design and Endpoints Single-arm, open label registrational Phase 3 study • Sample size: 134 patients with BCG-unresponsive disease ‒ 77 subjects with BGC-unresponsive CIS (Full enrollment expected Q1 2018) • Primary Endpoint ‒ CR a
Slide 25: Recent Vicinium Advances
© 2017 Eleven Biotherapeutics. All rights reserved. Recent Vicinium Advances • June 1, 2017 “Eleven Biotherapeutics Announced Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with ViciniumTM in Non- Muscle Invasive Bladder Cancer Based on Review of Safety
Slide 26: Our AstraZeneca & National Cancer Institute Collaboration
© 2017 Eleven Biotherapeutics. All rights reserved. Our AstraZeneca & National Cancer Institute Collaboration 26
Slide 27: Phase 1 Checkpoint Inhibitor Combination Vicinium + Durvalumab
© 2017 Eleven Biotherapeutics. All rights reserved. Phase 1 Checkpoint Inhibitor Combination Vicinium + Durvalumab in NMIBC • The clinical and preclinical observations that suggest VB4 (Vicinium and Proxinium) may induce anti-tumor immune responses have lead to a combination clinical study. • The NC
Slide 28: Treatment of Late-Stage SCCHN
© 2017 Eleven Biotherapeutics. All rights reserved. Treatment of Late-Stage SCCHN 28
Slide 29: Proxinium for Late-Stage SCCHN
© 2017 Eleven Biotherapeutics. All rights reserved. • Single chain anti-EpCAM antibody fragment fused with ETA • Late-stage SCCHN is dominated by the primary tumor ‒ 40-60% of deaths result from local or regional disease1 ‒ 90% of patients with disseminated disease die as a result of uncontrolled di
Slide 30: Proxinium Clinical Trial Results
© 2017 Eleven Biotherapeutics. All rights reserved. • Completed two Phase 1 trials, Russia (daily) and Brazil (weekly) ‒ Proxinium was generally well-tolerated ‒ Anti-tumor activity in 43% Russia trial, 62% Brazil trial ‒ Three out of the four patients with complete responses of their injected tumor
Slide 31: Proxinium: Responses in Injected & Non-Injected Tumors
© 2017 Eleven Biotherapeutics. All rights reserved. After four weeks of treatment Targeted tumor cell cytotoxicity may lead to cross-priming and immune therapy (T cell-mediated killing) of non-targeted tumors Injected Tumor Subject A: Subject B: Pre-treatment Injected Tumor Non-Injected Tumor Proxin
Slide 32: Proxinium: Phase 2/3 Clinical Trial Data
© 2017 Eleven Biotherapeutics. All rights reserved. Proxinium + BSC vs. BSC. Summarized Phase 2 and Phase 3 data1 RECIST criteria not employed Progression Stable Disease Response 1Only subjects with baseline and post-treatment tumor measurements are included (N = 36 for Proxinium + BSC; N = 26 for B
Slide 33: Proxinium: Clinical Development Plan
© 2017 Eleven Biotherapeutics. All rights reserved. • Observed responses in non-injected tumors during prior clinical trials and evidence from preclinical in vitro and animal studies suggest that Proxinium generates a host anti-tumor immune response that may improve the efficacy of checkpoint inhibi
Slide 34: De-Immunized Systemic Product Pipeline
© 2017 Eleven Biotherapeutics. All rights reserved. De-Immunized Systemic Product Pipeline Bouganvillea sp. deBouganin toxin 34
Slide 35: deBouganin: Next Generation Payload
© 2017 Eleven Biotherapeutics. All rights reserved. • Highly potent plant toxin ‒ Picomolar killing, avoidance of MDR, potentially effective against cancer stem cells ‒ Safety profile provides broad therapeutic window • Engineered de-immunized variant for systemic delivery • Type 1 ribosome inactiva
Slide 36: Corporate
© 2017 Eleven Biotherapeutics. All rights reserved. Corporate 36
Slide 37: Experienced Leadership Team
© 2017 Eleven Biotherapeutics. All rights reserved. Experienced Leadership Team Stephen Hurly President, CEO, and Director David Brooks, MD, PhD SVP Clinical Development Rich Fitzgerald Interim Chief Financial Officer (effective Oct 20, 2017) Greg Adams, PhD Chief Scientific Officer Glen MacDonald,
Slide 38: EBIO Corporate / Projected News Flow
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium + durvalumab NMIBC Phase 1 first patient treated Q4 2017 Vicinium NMIBC Phase 3 complete enrollment Q1 2018 Vicinium NMIBC Phase 3 topline three-month data Mid 2018 Vicinium + durvalumab NMIBC Phase 1 initial biomarker data Q3 2018 Viciniu
Slide 39: Targeting Cancer with POWER+PRECISION
© 2017 Eleven Biotherapeutics. All rights reserved. © 2017 Eleven Biotherapeutics. All rights reserved. Targeting Cancer with POWER+PRECISION™
Eleven Biotherapeutics — Investor Presentation (October 2017) on 6ix